Abstract:The combination of several drugs is often necessary, especially during long-term therapy. Drug-protein interaction has attracted a great deal of research interest because only the free drug fraction exerts pharmacological and/or toxicological effects. Herein, the binding interactions of serum transport protein, human serum albumin (HSA), with individual or combined anticancer drugs, (−)-epigallocatechin-3-gallate (EGCG) and 5-fluorouracil (FU), were investigated using isothermal titration calorimetry (ITC), circular dichroism (CD), and dynamic light scattering (DLS). DLS measurements showed that EGCG has a larger effect on the hydrodynamic diameter of HSA than FU. The adding order of EGCG and FU has an important influence on the size of the EGCG+FU+HSA complex. Fitting of the ITC data suggested that there are two sets of sites for the individual and combined binding of EGCG and FU to HSA. The obtained thermodynamic parameters revealed that electrostatic, hydrogen bonding, and van der Waals interactions may contribute to the stronger affinity of EGCG while hydrophobic interactions, van der Waals forces, and hydrogen bonding are the major forces in stabilizing the FU+HSA complex. The largest free concentrations of EGCG and FU are attained at pH7.4 and 8.4 respectively, due to the pH dependence on the number of binding sites and binding constants. The discrepancy in the free concentration between the binary and ternary systems implies the competitive binding of EGCG and FU to HSA. Changes in the secondary structure of HSA due to the addition of EGCG and FU at different pHs were discussed based on CD measurements. The calorimetric and spectroscopic results can provide quantitative information on the binding characteristics and suggest that the competitive binding of EGCG and FU to HSA may enhance anticancer effects. These results can provide a deeper understanding of combination therapy.

Thermodynamic and spectrographic studies on the interactions of ct-DNA with 5-fluorouracil and tegafur

Characterization of Interaction of Calf Thymus DNA with Gefitinib: Spectroscopic Methods and Molecular Docking

Thermodynamic and spectrographic study on DNA-calcium folinate complexation

Electrochemical and Spectroscopic Studies on Interaction between DNA and 5-Fluorouracil

Spectrophotometric Study of DNA Interactions with Ftorafur and Its Elementoorganic Derivatives

Study on the mechanism of the interaction between anticancer drug actinomycin D and calf thymus DNA by fluorescence method

Microcalorimetric and spectrographic studies on the interaction of DNA with betaxolol.

Thermodynamic Study on Interaction Between Anti-Tumor Drug 5-Fluorouracil and Human Serum Albumin

Analysis and Characterization of 5-Fluorouracil Based on Terahertz Spectroscopy

Spectroscopic studies on the interaction between carbaryl and calf thymus DNA with the use of ethidium bromide as a fluorescence probe.

Calorimetric and spectroscopic studies on the competitive behavior between (−)-epigallocatechin-3-gallate and 5-fluorouracil with human serum albumin

Thermochemistry Study on Interaction Between Anti-tumor Drug Tegafur and Bovine Serum Albumin

A Spectroscopic Study On The Dna Binding Behavior Of The Anticancer Drug Dacarbazine

The influence of 5-fluorouracil anticancer drug on the DNA base pairs; a quantum chemical study

Thermodynamic Study on the Interaction Between Anti-Tumor Drug Tegafur and Human Serum Albumin

Study on the interaction between Epirubicin-Fe2+ system and DNA by spectroscopic and electrochemical methods

Interactions of nucleic acid with anticancer drugs and generalized fluorescence quenching equation

Spectroscopic, Viscositic and Molecular Modeling Studies on the Interaction of 3′-Azido-daunorubicin Thiosemicarbazone with DNA

Spectroscopic study one thiosemicarbazone derivative with ctDNA using ethidium bromide as a fluorescence probe

Systematical investigation of binding interaction between novel ruthenium(II) arene complex with curcumin analogs and ctDNA.

Thermodynamics, in Vitro Release and Cytotoxity Studies on Doxorubicin–toluidine Blue O Combination Drugs Co-Loaded in Aptamer-Tethered DNA Nanostructures